The laboratory of clinical virology in monitoring patients undergoing monoclonal antibody therapy

This is the author's manuscript

Original Citation:

Availability:
This version is available http://hdl.handle.net/2318/96567 since

Published version:
DOI:10.1111/j.1469-0691.2011.03678.x

Terms of use:

Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
The laboratory of clinical virology in monitoring the patients undergoing monoclonal antibody therapy

Rossana Cavallo
Virology Unit, University-Hospital San Giovanni Battista di Torino, and Department of Public Health and Microbiology, University of Turin, Italy

Running title: Virology laboratory and mAbs.

Address:
Virology Unit
University Hospital San Giovanni Battista di Torino
Via Santena 9 – 10126 Torino, Italy
Phone +39(11)6705646
Fax +39(11)6705648
e-mail: rossana.cavallo@unito.it
Abstract

The relevant efficacy of monoclonal antibodies (mAbs) has resulted in the successful treatment of several diseases, although susceptibility to infections remains a major problem. This review summarizes aspects of the literature regarding viral infections and mAbs, specifically addressing the risk of infection/reactivation, the measures that can reduce this risk, and the role played by the laboratory of clinical virology in monitoring the patients undergoing mAb therapy.

Keywords

Monoclonal antibodies; herpesviruses; polyomaviruses; hepatitis viruses; monitoring.
Introduction

The treatment of several medical conditions, such as cancer and autoimmune diseases, has been revolutionized following the introduction of biologic therapies targeting specific components of pathways involved in the pathogenic mechanisms. These agents are prevalently monoclonal antibodies (mAbs). Immunotherapy developed with the discovery of antibodies structure and the introduction of hybridoma technology, which provided the first source of mAbs [1]. Initially, murine mAbs (suffix –omab) were burdened by major problems due to immune complex formation and inadequate recruitment of host effector functions. To overcome this, murine molecules were engineered to remove immunogenic content and to increase the immunomodulant efficiency; this was achieved by the production of chimeric (composed of murine variable regions fused onto human constant regions, ~65% human component; suffix –ximab) and humanized (produced by grafting murine hypervariable aminoacid domain into human antibodies, ~95% human component; suffix –zumab) antibodies. Extensive researches are currently conducted to originate mAbs for several diseases, such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases, and many types of neoplasms. However, susceptibility to infections remains a major concern, as the target of these mAbs are molecules or cells involved in immune anti-infectious pathways. The severity of these infections can be influenced by the protocol utilized (dosage, frequency, and route of administration). Considering the most used mAbs in clinical practice, the reported infectious complications remain low and limit particularly the utilization of mAbs targeting antigens such as CD52, CD20, tumor necrosis factor (TNF)-α and the integrin very late antigen (VLA)-4 [2]. Beside bacterial and fungal infections, viral infections/reactivations represent important factors limiting the utilization of biological agents (Table 1).
Anti-CD52: alemtuzumab

Alemtuzumab is a humanized anti-CD52 antibody (Campath®), that is mainly expressed on the surface of peripheral B- and T-cells, both normal and malignant, monocytes, thymocytes, natural killer cells and macrophages, whereas it is not expressed on erythrocytes or platelets. This mechanism of action makes alemtuzumab indicated for the treatment of chronic lymphocytic leukemia, non-Hodgkin lymphomas, post-transplantation and graft-versus-host disease. Treatment results in lymphoid ablation. In this context, reactivation of cytomegalovirus (CMV) is an important problem, having been reported in 6-66% of patients [3]. The wide range of reported incidence might be a result of differences in study design, population, and viral detection modes; moreover, earlier studies might have underreported the incidence of CMV reactivation, because CMV was not routinely monitored. Nevertheless, the benefit/risk ratio favors its utilization associated to a close virological monitoring for early detection of reactivation, as pre-emptive treatment prevents the occurrence of potentially life-threatening disease and the initiation of anti-CMV treatment avoids the interruption of alemtuzumab. Cytomegalovirus reactivation is typically observed between 4 and 6 weeks after the initiation of treatment [4]. Usually, given the high background of CMV-seropositivity, reactivation is monitored weekly by a sensitive detection method (CMV-DNAemia). In clinical trials, among the exclusion criteria for the recruitment, CMV-DNAemia positivity at screening makes the patient not eligible. Treatment to reduce viral load to a non-detectable level is required and study entry is possible once the infection has been treated. Among exclusion criteria, there are active or prior viral hepatitis B or C or positivity for hepatitis B serology. Patients with hepatitis B surface antibodies (HBsAb) with documented history of prior hepatitis B immunization are
eligible if other criteria are met (i.e. negativity for HBsAg, HBCab, and anti-HCV). Patients with HIV-infection are excluded. In Figure 1, an algorithm for the evaluation of viral infections in relation to the administration of alemtuzumab is reported.

**Anti-CD20: rituximab**

Rituximab (Mabthera® or Rituxan®) is a chimeric mAb targeting the CD20 molecule, that is expressed on the normal B-cell lineage (from pre-B stage to memory stage) as well as on abnormal B-lymphocytes. Rituximab has been approved for the treatment of indolent CD20, B-cell non-Hodgkin lymphomas, and chronic lymphocytic leukemia, as well as for that of moderate-to-severe rheumatoid arthritis. Several viral infections related to rituximab have been reported. In a metanalysis [5], 64 cases of serious viral infection after rituximab treatment were found, in particular HBV reactivation in patients with chronic lymphocytic leukemia and lymphomas [5,6-9], followed by CMV, varicella-zoster virus, and others. A close monitoring for viral infections, particularly HBV and CMV, by molecular methods is recommended. Periodic monitoring of HBV-DNA may predict HBV reactivation, thus being advantageous in terms of costs; it is also essential in cases with HBV-DNA mutations and when antibody expression is weak. The identification of HBV reactivation at an early stage is important; therefore, in addition to HBV-DNA monitoring, it should be recommended to evaluate changes in anti-HB titers [10]. Viral reactivation of polyomavirus JC from sites of latency leading to the development of infection and destruction of the oligodendrocytes is the pathogenic mechanism responsible for progressive multifocal leukoencephalopathy (PML). To date, 57 PML cases have occurred in patients treated with rituximab [11,12]. A high degree of awareness for PML facilitates case identification; as a definitive diagnosis of PML is based on clinical, neuroimaging, histopathologic findings, as well as on the
detection of JCV in the brain tissue, less invasive methods based on the detection of JCV-DNA in cerebrospinal fluid have been proposed. Evaluation of JCV-DNA on serum specimens seems to display low operating characteristics, given the rarity of PML and the high incidence of transient viremia (up to 18% in HIV-patients without PML)[13].

**Tumor necrosis factor-α antagonists**

Monoclonal antibodies that antagonize TNF-α (i.e. infliximab, etanercept, adalimumab, certolizumab pegol) are used for several inflammatory diseases, such as Crohn’s disease, rheumatoid polyarthritis, psoriasis, ankylosing spondylitis, and juvenile idiopathic arthritis. While the association with an increased risk of severe bacterial infections and reactivation of tuberculosis has been recognized, the impact on viral infections is less known. Long-term safety and efficacy in patients with chronic HBV or HCV and/or HIV infection are poorly known. However, history or current active HBV, history of HCV and HIV infection are exclusion criteria for enrollment in clinical trials. As regards HCV, elevated levels of TNF-α are associated with chronic infection and there is a growing evidence that the pathogenesis of hepatocyte destruction may be mediated by the upregulation of inflammatory cytokines such as TNF-α. Therefore, TNF-α antagonists may be beneficial when used in cases of HCV [14,15] and there are some reports indicating that anti-TNF-α therapy in the setting of HCV appears to be safe. However, as the role of TNF-α is complex, the FDA points out the possible risk of reactivation of chronic viral hepatitis. Overall, data on safety and efficacy are conflicting; therefore, the presence of HCV should not be an absolute contraindication, given an appropriate pretreatment screening and a close monitoring. For selected patients, anti-TNF-α therapy in the setting of HCV appears to be safe without apparent influence on the underlying infection. Interval monitoring of
serum aminotransferases and HCV viral load is recommended. Elevated levels of TNF-α are also seen in patients with chronic HBV and, in these patients, it may play a role in clearing and controlling replication by synergizing with interferon; inhibition of TNF-α could theoretically lead to enhanced viral replication [16,17]. Reports of patients with chronic HBV who were treated with infliximab or etanercept, and developed a severe reactivation, sometimes with fulminant hepatitis, have been published [18-21]. In most cases, patients had chronic HBV with HBsAg positivity, but in others fulminant hepatitis was associated with a previously unrecognized HBsAg-carrier condition. For HBsAg-negative patients with a known history of HBV, the risk of reactivation is very low, but it cannot be totally excluded. Patients who are persistently HBsAg-negative, but have an occult HBV infection, have also been described. These patients may be at risk of developing a flare of hepatitis during the course of anti-TNF-α agents as this may interrupt the suppression of viral replication and gene expression typical for the occult HBV [17]. Evaluation of risk-benefit profile for specific antiviral treatment with lamivudine should be performed [17]. In conclusion, screening for HBV in all patients prior to treatment with anti-TNF-α agents should be recommended and, if treatment has been initiated, carriers of HBV should be closely monitored for laboratory and clinical signs of viral reactivation during therapy and for several months following its termination.

Few data on the risk of reactivation of herpesvirus infections are available. Several cases of CMV infection have been reported, although severe clinical manifestations are rare. Authors suggested the assessment of CMV pp65-antigen levels or quantification of CMV-DNA in symptomatic patients [22-26]. Limited informations are available on Epstein-Barr virus reactivation, as well as JCV. Large studies with long follow-up are needed to define the risk and opportunity for viral monitoring. Epstein-Barr virus is associated with
lymphoproliferative diseases in immunosuppressed patients and infliximab treatment has resulted in transient elevations in viral load in some patients, although at levels lower than those associated to lymphoproliferative disorders [27]. Similarly, also limited data are available on varicella zoster virus and screening recommendations for the presence of antibodies prior to treatment or a prophylactic vaccination in non-immune patients remain questionable [28].

Specific effects of anti-TNF-α therapy on human papillomavirus-associated diseases remain unknown, with very few reports suggesting a significantly increased risk in patients with inflammatory bowel diseases treated with infliximab [29].

HIV is considered among the relative contraindications for anti-TNF-α therapy, however its safety in HIV-infected patients is unknown. Their use should be reserved for highly selected patients, although further studies are needed. The potential impact of the loss of HIV control needs to be determined before establishing a clear recommendation; to promptly identify reactivation of HIV, close monitoring of clinical and laboratory parameters in these patients is mandatory [17,30].

Overall, although several guidelines regarding viral infections monitoring in immunocompromised patients are available, few address biological therapy. The appropriate serological tests are poorly defined, although evaluation of HBV status is widely supported, while HCV and HIV testing seems to be justified in high-risk patients. The European Crohn’s and Colitis Organisation consensus statement recommends universal testing (HBsAg, anti-HBs, anti-HBc) and HBV vaccination in all the patients with inflammatory bowel diseases, while no recommendations have been defined for HCV [31].

On the contrary, a consensus statement on pre-treatment testing in rheumatology patients
recommends the screening for HBV and HCV in all the patients, without a defined serological strategy [32].

**Anti-integrin VLA-4**

Natalizumab (Tysabri®) is a selective adhesion molecule inhibitor the target of which is the α4 subunit of VLA-4 receptor. Natalizumab binds to α4-integrin expressed on the surface of activated T cells and other mononuclear leukocytes, where it prevents adhesion between the endothelial cell and the immune cell. This action inhibits the migration of leukocytes into the central nervous system. The main indication for natalizumab treatment is relapsing-remitting highly inflammatory multiple sclerosis (MS). However, the same mechanism of action implies a decreased local immune surveillance, thus possibly contributing to an increased risk of PML, a demyelinating disease caused by lytic replication of JCV in oligodendrocytes, that is observed in the setting of profound cellular immunosuppression, such as HIV patients and individuals exposed to potent antilymphocyte drugs, such as natalizumab, and other mAbs, such as rituximab and efalizumab.

More than 30 PML cases have been reported worldwide in patients receiving natalizumab monotherapy for MS and data suggests that PML incidence increases with the number of infusions (increased risk after two years of therapy). Currently, ~30,000 patients treated or on treatment with natalizumab are being monitored for PML [12].

**Conclusions**
The elevated efficacy of mAbs is counterbalanced by an increased risk of infectious complications. The complete spectrum of viral diseases complicating their administration is still poorly known, although data are accumulating. Similarly, also virological screening and monitoring that should be performed in these patients are still undefined and vary largely depending on underlying disease, type of patients, and protocol. Particular attention is required for the monitoring of herpesviruses, JCV, HBV and HCV, and data that are being obtained could represent the basis to define consensus guidelines that take into account the evaluation of viral status pre-treatment, as well as viral replication/reactivation during therapy and following its interruption. The possible role played by the specific cellular immune response in containing viral replication remains to be determined and it is likely that viro-immunological monitoring could contribute to better understand the immunological background underlying the occurrence of viral complications and to improve their clinical management. Overall, the role played by the virology laboratory is relevant as the basal evaluation of viral infection and the subsequent monitoring in patients treated with biological agents could allow to start or continue a successful therapy in cases for which there are few treatment options. As the benefits of these agents outweigh their risks, the formulation of specific recommendations could allow to identify a small group of patients in which the treatment cannot be used or must be interrupted. The aim of developing specific recommendations and guidelines is becoming all the most important considering the growing utilization of these agents in different clinical contexts.

Conflict of interests. None.
References


Table 1. Main viral infections/reactivations in patients undergoing monoclonal antibodies therapy and monitoring or recommendations. PTLD, post-transplantation lymphoproliferative disorders.

<table>
<thead>
<tr>
<th></th>
<th>Anti-CD52 (alentuzumab)</th>
<th>Anti-CD20 (rituximab)</th>
<th>TNF-α antagonists (infliximab, etanercept, adalimumab, certolizumab pegol)</th>
<th>Anti-integrin VLA-4 (natalizumab)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMV</td>
<td>6-66% reactivation within 4-6 weeks, close monitoring (3,4)</td>
<td>Few cases, close monitoring (5)</td>
<td>Poorly known (22-26)</td>
<td></td>
</tr>
<tr>
<td>HBV</td>
<td>Active and prior infection as exclusion criteria in clinical trials</td>
<td>20-55%, close monitoring (5-10)</td>
<td>Case reports, close monitoring, exclusion criteria in clinical trials, but consider occult infection (18-21)</td>
<td></td>
</tr>
<tr>
<td>HCV</td>
<td>Active and prior infection as exclusion criteria in clinical trials</td>
<td>Poorly known, close monitoring (14,15)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VZV</td>
<td>Few cases (5)</td>
<td>Poorly known (28)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>JCV</td>
<td>57 cases (11,12)</td>
<td>30 cases (12)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBV</td>
<td>Up to 40% reactivation, &lt;1% risk PTLD (33)</td>
<td>Poorly known (27)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV</td>
<td></td>
<td>Poorly known (29)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 1. Algorithm for the evaluation of viral infections in relation to the administration of alemtuzumab.

- **Test CMV–DNA before treatment with alemtuzumab**
  - **Negative**: Start alemtuzumab and monitor CMV–DNA weekly.
  - **Positive**: Antiviral treatment to reduce viral load to a non-detectable level, then start alemtuzumab.

- **Active or prior viral hepatitis B or C or positive serological markers for HBV**
  - **No treatment with alemtuzumab**
  - **HBsAb positive**
    - **Negative for HBsAg, HBeAb, anti-HCV**: Treatment with alemtuzumab.
    - **Positive for HbsAg, HBeAb or anti-HCV**: No treatment with alemtuzumab.